<DOC>
	<DOCNO>NCT00005001</DOCNO>
	<brief_summary>The purpose study see give HIV-positive patient HIV vaccine plus anti-HIV drug help low HIV level blood ( viral load ) .</brief_summary>
	<brief_title>Safety Effectiveness Treating HIV-Positive Patients With HIV Vaccine ( Remune )</brief_title>
	<detailed_description>At time study entry , patient receive HAART regimen consist three drug least two class antiretroviral drug . Upon enter study , patient receive Remune IFA Weeks 0 , 12 , 24 . Patients remain study 40 week . Patients receive three injection Remune IFA whose plasma HIV-1 RNA level le 50 copies/ml Week 26 discontinue HAART Week 28 . ( If patient plasma HIV-1 RNA level 50 copies/ml Week 26 , he/she must measurement 50 copies/ml Week 27 proceed HAART discontinuation Week 28 . If Week 27 patient plasma HIV-1 RNA level 50 copies/ml , patient discontinue HAART remain study study visit Weeks 34 40 . ) Patients discontinue HAART plasma HIV-1 RNA level measure day HAART discontinue Days 3 , 5 , 7 , 10 , 14 , 21 , 28 , 35 , 42 discontinuation . Patients plasma HIV-1 RNA level least 5,000 copies/ml Week 34 restart HAART time . ( Patients whose plasma HIV-1 RNA level reach great equal 100,000 copies/ml two occasion Week 34 option restart HAART immediately . ) Patients whose plasma HIV-1 RNA level le 5,000 copies/ml Week 34 restart HAART unless level increase least 5,000 copies/ml . Patients discontinue HAART monitor intensively duration study . Patients 27 visit stay study completion Week 40 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Are receive antiHIV drug combination contain three drug least two class antiHIV drug ( protease inhibitor ) . Patients must receive drug combination least 6 month study entry . Before begin drug combination , patient must take either antiHIV drug one two nucleoside analogue ( NRTIs ) . Had viral load 5,000 100,000 copies/ml begin current antiHIV therapy . Have viral load 50 copies/ml current antiHIV therapy within 2 week study entry . Have CD4 count great 350 cells/mm3 time study entry . Are least 13 year old ( consent parent guardian require 18 ) .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>remune</keyword>
</DOC>